Cellumed Co.,Ltd. (KOSDAQ:049180)
1,009.00
-101.00 (-9.10%)
At close: Mar 16, 2026
Cellumed Revenue
Cellumed had revenue of 23.42B KRW in the quarter ending March 31, 2026, a decrease of -40.33%. This brings the company's revenue in the last twelve months to 124.37B, down -12.49% year-over-year. In the year 2025, Cellumed had annual revenue of 140.19B with 8.56% growth.
Revenue (ttm)
124.37B
Revenue Growth
-12.49%
P/S Ratio
0.67
Revenue / Employee
1.38B
Employees
90
Market Cap
83.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 140.19B | 11.05B | 8.56% |
| Dec 31, 2024 | 129.14B | 33.59B | 35.15% |
| Dec 31, 2023 | 95.55B | -26.53B | -21.73% |
| Dec 31, 2022 | 122.09B | 22.17B | 22.19% |
| Dec 31, 2021 | 99.92B | 26.73B | 36.52% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LOGEN | 794.58B |
| CoAsia | 392.99B |
| JLS Co.,Ltd. | 102.72B |
| Samik Pharmaceutical Company LTD. | 61.48B |
| KISTRON | 55.94B |
| RSUPPORT | 48.60B |
| GIGALANE | 41.34B |
| MX On CORPORATION | 36.20B |